Skip to content

Author

A. Vankerckhoven

We have 1 of 23 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Preclinical characterization of a reversible XPO1 inhibitor for cancer therapy

The authors design and characterise FR-027, a reversible covalent inhibitor of XPO1 that does not induce XPO1 degradation, demonstrating strong antitumour activity, including in brain tumours, with an improved safety profile in mice.

Janne Van Hauwenhuyse, F. Reniers, L. Persoons et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.